

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Enhanced sphingosine-1-phosphate levels by pharmacological or genetic approaches attenuate cardiac dysfunction in experimental septic cardiomyopathy**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1563299> since 2016-05-29T18:02:05Z

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

***Enhanced sphingosine-1-phosphate levels by pharmacological or genetic approaches attenuate cardiac dysfunction in experimental septic cardiomyopathy***

SM Coldewey, E Benetti, M Collino, M Bauer, A Huwiler, C Thiemermann.

**Introduction:** The role of Sphingosine-1-phosphate (S1P) and its receptors S1PR<sub>1-5</sub> in septic cardiomyopathy is not known. The S1P mimetic FTY720-P acts as an agonist on S1PR<sub>1</sub> and S1PR<sub>3-5</sub> and a functional antagonist on S1PR<sub>2</sub>.

**Methods:** Cardiomyopathy was mimicked by co-administration of the bacterial cell-wall components lipopolysaccharide (LPS) and peptidoglycan (PepG) in wild-type (WT) and sphingosine kinase 2 deficient mice (SPHK2<sup>-/-</sup>). At 1h after LPS/PepG mice received FTY720 alone, or they received a phosphatidylinositol 3 kinase (PI3K) inhibitor or a S1P<sub>2</sub> receptor antagonist prior to FTY720. 18h later cardiac function was assessed by echocardiography, serum-S1P was measured by LC/MS/MS and expression of signalling molecules was determined by immunoblot analysis.

**Results:** Compared to sham, mice subjected to LPS/PepG demonstrated a reduction in ejection fraction (EF) as well as a decrease of serum-S1P. In SPHK2<sup>-/-</sup>-mice, which have higher endogenous S1P-levels, LPS/PepG-induced reduction of EF was lower than in WT-mice. Treatment with FTY720 attenuated the impaired EF in WT-mice accompanied by an increase of serum-S1P and an increased phosphorylation of AKT and eNOS in heart tissue. Cardioprotective effects of FTY720 were abolished following co-administration of either a PI3K inhibitor or a S1P<sub>2</sub> antagonist. **Conclusion:** We show here for the first time that the impaired left ventricular systolic contractility caused by LPS/PepG is attenuated by a pharmacological or genetic approach to alter S1P-serum levels. Mechanistically, our results indicate that activation of S1PR<sub>2</sub> by increased serum S1P and the subsequent activation of PI3K signalling contribute to the observed cardioprotective effect of FTY720 in experimental sepsis.